This document relates to materials and methods for the production of protein. For example, proteins having a low flavor or low color profile and food products comprising the same.

Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.

The invention provides methods of testing food for antigens that are more stable to food processing than more clinically problematic allergens from the same food. When clinically-significant allergens are disproportionately broken down by common preparation methods, the presence of certain food ingredients may be “masked” to some tests yet may still be allergenic. To prevent false negative results due to food preparation, the invention provides tests that test for specific food antigens that are selected on the basis of their stability under processing. Antigens are selected for inclusion in the test not because they are the most clinically relevant allergens, but rather because they are robust to processing (e.g., and do not denature during cooking). Tests of the invention may also test for the most clinically relevant allergens, but importantly, by testing for stable protein products/antigens, the tests report the presence of food residues even after commercial processing.

Gene sequences are tailored for protein expression by measuring ribosome dynamics, training a statistical model of the relationship between DNA sequence and translation speed; and using this model to design an optimal DNA sequence encoding a given protein.

Compounds, compositions, and methods for treating and/or preventing a neurological disease, a neuropsychiatric disease, a neurodegenerative disease, preferably narcolepsy and associated diseases or disorders.

Methods for selecting polypeptides or proteins having one or more desired properties from a library of sequences expressed in eukaryotic cells, including: encapsulating the cells by photopolymerization; solubilizing the encapsulated cells to produce semipermeable microcapsules; optionally contacting the cells and/or the microcapsules with one or more agents to facilitate detection of activity or function of polypeptides or proteins of interest; and selecting polypeptides or proteins of interest having one or more desired properties. Also provided are methods for encapsulating eukaryotic cells for use in the selection of polypeptides and proteins as described above.

The invention relates to an in silico screening method to identify candidate excipients for reducing aggregation of a protein in a formulation. The method combines computational molecular modeling and molecular dynamics simulations to identify sites on a protein where non-specific self-interaction and interaction of different test excipients may occur, determine the relative binding energies of such interactions, and select one or more test excipients that meet specified interaction criteria for use as candidate excipients in empirical screening studies.

The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.

The present invention relates to a method for measuring characteristics of particles in solution and to a device for performing the same, wherein said method comprises the steps of providing a vessel comprising a sample of said particles in solution, wherein the sample has preferably a volume between 0.1 μL and 15 μL, providing a monochromatic light source and a light detector, transmitting light from the monochromatic light source to the vessel comprising the sample, detecting light emitted from the vessel with the light detector, and determining characteristics of said particles in solution comprised in the sample based on a dynamic light scattering (DLS) measurement.

The present invention describes methods of using Olfr90 demonstrated to bind to fungal metabolites, including a metabolite known to be detected in patients with mold (e.g. Aspergillus) infections.